ADMA Biologics Reports 2% Revenue Growth to $124.4 Million in Q2 2026

ADMA Biologics, Inc. reported its financial results for the second quarter of 2026, revealing a total revenue of $124.4 million, a 2% increase from $122.0 million in the same period last year. The growth was primarily driven by a significant rise in sales of its product ASCENIV, which saw an increase of $19.6 million, reflecting continued market acceptance. However, sales of BIVIGAM decreased by $18.3 million due to competitive pressures in the immune globulin market. The company achieved a gross profit of $86.3 million, resulting in a gross margin of 69.4%, up from 55.1% in the prior year, attributed to a favorable product mix and benefits from a yield enhancement manufacturing process.

In terms of profitability, ADMA reported a net income of $37.8 million for the quarter, compared to $34.2 million in the previous year, marking a 10.5% increase. The company’s operating income also rose to $52.4 million, up from $42.8 million in the same quarter of 2025. Research and development expenses surged to $6.0 million, reflecting increased clinical development activities related to the SG-001 project. Selling, general, and administrative expenses increased by 20.4% to $26.7 million, driven by higher employee-related costs and legal fees.

ADMA's operational metrics indicate a strategic shift, as the company divested three plasma collection centers for $12 million, which is expected to enhance capital efficiency and support increased production capacity for ASCENIV. The company currently operates seven plasma collection centers, which are crucial for sourcing the plasma needed for its products. The total assets of ADMA increased to $684.2 million as of June 30, 2026, compared to $624.2 million at the end of 2025, with cash and cash equivalents rising to $136.0 million.

Looking ahead, ADMA remains optimistic about its growth trajectory, particularly with the anticipated benefits from its yield enhancement production process and the expansion of ASCENIV's label to include pediatric patients. However, the company also faces challenges, including increased competition in the IVIG market and potential impacts from ongoing economic conditions. ADMA's management has indicated that they expect to maintain sufficient cash flow to support operations without the need for additional capital in the near term, although they remain vigilant regarding market conditions that could necessitate further financing.